{
	"kja6j70xText": "Boulenger JP et al. 2012<span class=\"fs1 ls5 v1\">1</span>",
	"kja6j70yText": "A double<span class=\"_ _0\"></span>-blind, placebo<span class=\"_ _0\"></span>-<span class=\"_ _0\"></span>controlled, randomised,<span class=\"_ _0\"></span> clinical s<span class=\"_ _0\"></span>tudy o<span class=\"_ _0\"></span>f Brintellix® in th<span class=\"_ _0\"></span>e <br><span class=\"ls17 ws25\">prevention of relapse in patient<span class=\"_ _0\"></span>s with<span class=\"_ _0\"></span> major depressive disorder<span class=\"_ _c\"></span>.</span>",
	"kja6j70zText": "Study objective: <span class=\"ff3\">Evalua<span class=\"_ _2\"></span>te the efficacy of Brintellix® vs. placebo in the pr<span class=\"_ _2\"></span>evention of<span class=\"_ _0\"></span> <br>relapse of MDEs as well as long-term safety and tolerability of Brintellix® vs. placebo.</span>",
	"kja6j710Text": "After a 12-week <br>open label period, <br>where 639 patients <br>with MADRS total score <br>≥26 were trea<span class=\"_ _2\"></span>ted with <br>Brintellix® 5 mg or 10 mg, <br>patient who remitted <br>(MADRS score ≤10) were <br>randomised to either <br>Brintellix® or placebo<span class=\"_ _0\"></span> <br>for 24-64 weeks",
	"kja6j711Text": "All non-withdrawn",
	"kja6j712Text": "patients (placebo n=104, ",
	"kja6j713Text": "Brintellix® n=125) ",
	"kja6j714Text": "completed the study when ",
	"kja6j715Text": "the last patient completed ",
	"kja6j716Text": "24 weeks of double-blind ",
	"kja6j717Text": "treatment.<span class=\"_ _c\"></span> Safety<span class=\"_ _0\"></span> ",
	"kja6j718Text": "follow-up four weeks ",
	"kja6j719Text": "after study completion ",
	"kja6j71aText": "or withdrawal",
	"kja6j71bText": "Back",
	"kja6j71cText": "Patients who <br><span class=\"ls46 ws7b\">relapsed<span class=\"_ _0\"></span> <br><span class=\"ls3c ws86\">(M<span class=\"_ _0\"></span>A<span class=\"_ _0\"></span>D<span class=\"_ _0\"></span>R<span class=\"_ _0\"></span>S<span class=\"_ _0\"></span> ≥22)<span class=\"_ _1\"></span> <br><span class=\"ls1a wsb\">were with drawn <br>from the study</span></span></span>",
	"kja6j71dText": "Primary analysis:<span class=\"ff3 ls37 ws7d\"> time<span class=\"_ _0\"></span> to relapse<span class=\"_ _0\"></span> (full-analys<span class=\"_ _0\"></span>is se<span class=\"_ _0\"></span>t,<span class=\"_ _0\"></span> <br><span class=\"ls36 wsb\">Cox p<span class=\"_ _2\"></span>ropo<span class=\"_ _2\"></span>r<span class=\"_ _0\"></span>tion<span class=\"_ _2\"></span>al haza<span class=\"_ _2\"></span>rd mod<span class=\"_ _2\"></span>el<span class=\"_ _2\"></span>) withi<span class=\"_ _2\"></span>n the first 2<span class=\"_ _c\"></span>4 weeks <br><span class=\"ls38 ws7e\">of the double-<span class=\"_ _0\"></span>blind period.</span></span></span>",
	"kja6j71eText": "Secondary analysis: <span class=\"ff3\">ti<span class=\"_ _2\"></span>me to re<span class=\"_ _2\"></span>lap<span class=\"_ _2\"></span>se cons<span class=\"_ _2\"></span>ideri<span class=\"_ _2\"></span>ng al<span class=\"_ _2\"></span>l <br><span class=\"ls47 ws6d\">relapse<span class=\"_ _0\"></span>s tha<span class=\"_ _0\"></span>t occ<span class=\"_ _0\"></span>urred<span class=\"_ _0\"></span> during<span class=\"_ _0\"></span> the<span class=\"_ _0\"></span> entire<span class=\"_ _0\"></span> double<span class=\"_ _0\"></span>-blind<span class=\"_ _0\"></span> <br></span>period (<span class=\"_ _3\"></span>up to 64 weeks<span class=\"_ _3\"></span>).</span>",
	"kja6j71fText": "Brintellix® 5 mg or 10 mg (n=204)",
	"kja6j71gText": "Placebo (n=192)",
	"Brintellix_852e830037": "<span class=\"ff2 fc0 fs13\">References</span>",
	"Brintellix_85059e822e": "<div class=\"ff3 fc1\" style=\"font-size:15px;\"><span class=\"ff2\">1.</span> Boulenger JP et al. J Psychopharmacol 2012;26:1408-1416.</div>"
}
